Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19
Status:
Completed
Trial end date:
2021-11-14
Target enrollment:
Participant gender:
Summary
This study is a multi-centre randomized controlled trial involving severe covid-19 patients.
The intervention group will receive mesenchymal stem cell secretomes and standard covid-19
therapy, while the control group receive placebo and standard covid-19 therapy. Clinical
presentation, inflamatory marker, laboratory and radiological parameters, RT-PCR conversion,
safety profile, and mortality rate will be monitored for a maximum of 14 days after
intervention.